ArticleBMC medicine2025
Impact of piR_004530 reactivation in lung cancer: implications for recurrence and survival of lung squamous cell carcinoma patients.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative multi-omics and mendelian randomization reveal the critical role of pyroptosis in prognosis and therapy of lung squamous cell carcinomas.Frontiers in cell and developmental biology · 2026Article
- piR-37524 Overexpression in Colorectal Cancer: A Potential Diagnostic Bio-Marker and Therapeutic Target.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPIWI-interacting RNAs (piRNAs) are germline-characteristic small noncoding RNAs whose reactivation has been recently observed during carcinogenesis because of the germline reactivation program, which can be considered a hallmark of cancer. We evaluated the prognostic impact of hsa_piR_004530 reactivation in non-small cell lung cancer (NSCLC) and studied its functional role in cell lines and organoids.
methodsA total of 243 NSCLC resected patients were analyzed. Hsa_piR_004530 expression was quantified in tumor (n = 243) and normal tissue (n = 31) using qRT-PCR. Tumor recurrence, disease-free survival (DFS), and overall survival (OS) were used as clinical endpoints in survival analysis. Cox regression models were generated, and decision curve analysis for assessment of clinical benefit on disease prognosis was used. The effect of hsa_piR_004530 overexpression was assessed in NSCLC cell lines by cell migration, invasion, proliferation, apoptosis, and colony formation analysis. Patient-derived organoids from SCC patients were generated, and cell viability was evaluated after piRNA overexpression.
resultsHsa_piR_004530 became reactivated on the tumor compared to normal tissue and was overexpressed in SCC patients. The prognosis analysis in the whole cohort showed that patients with high levels of hsa_piR_004530 had shorter DFS and OS. However, the subanalysis by histology revealed that the true prognostic impact of hsa_piR_004530 was specifically on SCC patients. These results became validated in an additional cohort. SCC patients with high hsa_piR_004530 had a higher relapse rate and shorter DFS and OS. Hsa_piR_004530 emerged as an independent prognostic factor in the multivariate analysis. Since the SCC patients who received adjuvant treatment had the best postsurgical prognosis, we focused on the role of hsa_piR_004530 on non-treated patients, which allowed us to identify a high-risk group where the piRNA ameliorated patients' risk stratification, highlighting superior clinical benefit in postsurgical relapse prediction. Hsa_piR_004530 overexpression was associated with increased migration, invasion, and colony formation. Moreover, the overexpression induced stem cell gene activation and correlated with higher size spheroid formation. In patient-derived organoids, the overexpression boosted organoid cell viability.
conclusionsHsa_piR_004530 became reactivated in NSCLC, where it played a role as an oncogene, and its higher levels correlated with disease recurrence and shorter survival in SCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.